Samlyn Capital’s Pfizer PFE Stock Holding History

Samlyn Capital’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-7,291,751	Closed	-$193M	–	104
2024 Q4	$193M	Sell	7,291,751 -625,600	-8%	-$17M	2.92%	7
2024 Q3	$229M	Buy	7,917,351 +3,010,648	+61%	+$87.8M	3.47%	3
2024 Q2	$137M	Buy	4,906,703 +1,446,582	+42%	+$39.8M	2.29%	14
2024 Q1	$96M	Buy	3,460,121 +2,013,275	+139%	+$55.9M	1.61%	22
2023 Q4	$41.7M	Buy	+1,446,846	New	+$43.7M	0.83%	38
2020 Q2	–	Sell	-823,133	Closed	-$25.5M	–	123
2020 Q1	$25.5M	Buy	+823,133	New	+$28M	0.64%	48
2016 Q2	–	Sell	-2,657,374	Closed	-$74.7M	–	132
2016 Q1	$74.7M	Sell	2,657,374 -57,730	-2%	-$1.65M	1.61%	24
2015 Q4	$83.2M	Buy	+2,715,104	New	+$85.4M	1.72%	20

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

TIM

Thornburg Investment Management Santa Fe, New Mexico $9.63B AUM 35.65% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Samlyn Capital's PFE Position: Q1 2025 in Review

Samlyn Capital sold out of Pfizer (PFE) in Q1 2025, closing a stake of 7,291,751 shares — an estimated $193M sold.

Samlyn Capital first reported a position in PFE in Q4 2015 and held it in 8 quarters. The position peaked at $229M in Q3 2024. 2,930 funds tracked by Wall St. Rank hold PFE as of Q1 2025.

Samlyn Capital reported no remaining Pfizer position as of Q1 2025 after selling out during the quarter.
Samlyn Capital sold 7,291,751 Pfizer shares in Q1 2025, an estimated $193M.
Samlyn Capital first reported a position in Pfizer in Q4 2015 and held it in 8 quarters.
Samlyn Capital's Pfizer position peaked at $229M in Q3 2024.
2,930 funds tracked by Wall St. Rank held Pfizer as of Q1 2025.

Based on Samlyn Capital's 13F filing for Q1 2025, filed 15 May 2025.